2013

Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey

Background/aim: The purpose of the study is to determine the cost-effectiveness of the chemotherapy medications that contain gemcitabine and pemetrexed, which are used in the treatment of advanced nonsmall cell lung cancer (NSCLC). Materials and methods: The study evaluated the effectiveness and cost of platinum-based pemetrexed and gemcitabine treatments as the first-line treatment of advanced NSCLC with the use of the Markov model, and from the perspective of the Social Security Institution. NSCLC costs calculated on the basis of experts opinions and the effectiveness values calculated by administering the EQ-5D questionnaire to the patients were analyzed. All direct medical costs were included in the model. Results: While the life-long cost of gemcitabine/cisplatin treatment was determined to be 10,347.45 Turkish lira per patient, it was determined as 17,783.34 for pemetrexed/cisplatin treatment. The incremental cost of pemetrexed/cisplatin treatment is 220,754 per quality-adjusted life year. Conclusion: Although there is no official threshold value in Turkey, due to the fact that the incremental cost effectiveness ratio exceeds the threshold value calculated on the basis of GDP per capita, it is understood that pemetrexed/cisplatin is not cost-effective in the firstline treatment of advanced NSCLC.

PDF

___

1. Uyl-de Groot CA. Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care. Eur J Cancer 2006; 42: 28622866.
2. GLOBOCAN. GLOBOCAN Project. Lyon, France: IARC. Available online at http://globocan.iarc.fr.
3. Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review. J Clin Oncol 1998; 16: 39003912.
4. Berger ML, Bingefors K, Hedblom EC, Pashos CL, Torrance GW. Health Care Cost, Quality, and Outcomes. Lawrenceville, NJ, USA: ISPOR; 2003.
5. Tatar M, Wertheimer AI. Sağlık Teknolojilerinin Değerlendirilmesiİlaç Geri Ödeme Kararları İçin Bir Model Önerisi. Ankara, Turkey: MN Medikal ve Nobel Press; 2010 (in Turkish).
6. TÜİK. News Bulletin No: 13471. Ankara, Turkey: TÜİK.
7. Göksel T, Yıldız P, Altın S, Başer S, Bayız H, Görgüner M, Yurdakul AS. Akciğer kanseri. In: Metintaş M, editor. Türkiyede Temel Akciğer Sağlığı Sorunları ve Çözüm Önerileri. Ankara, Turkey: Sentez Press; 2010. pp. 5571 (in Turkish).
8. NICE. Pemetrexed for the First-Line Treatment of Non-SmallCell Lung Cancer. London, UK: National Institute for Health and Care Excellence; 2010.
9. Evans WK. Cost-effectiveness of gemcitabine in stage IV nonsmall cell lung cancer: an estimate using the Population Health Model lung cancer module. Semin Oncol 1997; 24: 5663.
10. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinolbine in non-small cell lung cancer: a systematic review. Thorax 2002; 57: 2028.
11. Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D. Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer. Pharmacoeconomics 2002; 20: 325337.
12. Szczepura A. Healthcare outcomes: gemcitabine costeffectiveness in the treatment of non-small cell lung cancer. Lung Cancer 2002; 38: S21S28.
13. Uyl-de Groot CA, McDonnell J, Groen HJM, Radice D, ten Velde G. Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small cell lung cancer: results of a Markov chain model. Eur J Hosp Pharm 2005; 11: 3741.
14. Toschi L, Finocchiaro G, Ceresoli GL, Zucali PA, Cavina R, Garassino I, de Vincenzo F, Santoro A, Cappuzzo F. Is gemcitabine cost effective in cancer treatment? Expert Rev Pharm Out Res 2007; 7: 239249.
15. Bongers ML, Coupé VMH, Jansma EP, Smit EF, Uyl-de Groot CA. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review. Pharmacoeconomics 2012; 30: 1734.
16. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 35433551.